01 February 2006
The influence of different treatment modalities on clinical improvement and reduction of cyclosporine A-induced gingival overgrowth
Małgorzata Radwan- Oczko, Maria BoratyńskaCase Rep Clin Pract Rev 2006; 7:58-63 :: ID: 446799
Abstract
Background: The prevalence of gingival overgrowth in renal transplant recipients maintained on cyclosporine
A remains as essential and still unexplained problem for the patient, physician and periodontist.
Clinically significant gingival overgrowth may be associated with inflammation, pain, tooth migration, mastication and cosmetic disorders and it may cause physiological and psychological morbidity. Tacrolimus is a new immunosuppressant, a therapeutic alternative to CsA and has no adverse effect on the gingival tissues.
Case Report: We reported on a case of five patients after renal transplantation with severe CsA – induced
gingival overgrowth and different treatment modalities. Two of them underwent periodontal
therapy and surgical treatment - gingivectomy. The next three patients were converted from CsA to tacrolimus. Hygiene instructions to all patients were given. After 2 years in surgery treated patients gingival overgrowth, degree and inflammation level were lower but still present. In patients converted to tacrolimus treatment almost complete regression of the gingival overgrowth without surgical intervention were observed.
Conclusions: Both periodontist and patient have an important role to play in improving oral hygiene and
gingival health. Cyclosporine-induced gingival overgrowth is effectively ameliorated by conversion
from CsA to tacrolimus while surgical intervention provides only temporary remedy.
Keywords: Cyclosporine A, Gingival Overgrowth, Tacrolimus, periodontal treatment, Gingivectomy
SARS-CoV-2/COVID-19
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938730
21 March 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938659
22 February 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938732
22 February 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938761
In Press
22 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.938774
22 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939650
22 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939530
22 Mar 2023 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.939117
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
07 Dec 2021 : Case report
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347